Serum endocan as a dual-function biomarker in Kawasaki disease: early diagnostic potential and prediction of coronary arterial aneurysms

IF 3.6 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cytokine Pub Date : 2025-12-01 Epub Date: 2025-10-22 DOI:10.1016/j.cyto.2025.157052

Chang Liu, Yi Wei, Fengchuan Jing , Qijian Yi

{"title":"Serum endocan as a dual-function biomarker in Kawasaki disease: early diagnostic potential and prediction of coronary arterial aneurysms","authors":"Chang Liu, Yi Wei, Fengchuan Jing , Qijian Yi","doi":"10.1016/j.cyto.2025.157052","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Kawasaki disease (KD), an acute vasculitis of unclear etiology, is an important contributor to childhood-acquired heart disease due to coronary arterial aneurysms (CAAs). Current diagnosis lacks specific biomarkers, risking delayed treatment. Endocan, a proteoglycan implicated in vascular inflammation, may address this gap. This study evaluates serum endocan in acute KD for its utility in early KD diagnosis and CAA risk prediction.</div></div><div><h3>Method</h3><div>This prospective cohort study enrolled 79 KD patients and 48 healthy controls. The KD group was further divided into KD with CAA (KD-CAA) and KD non-CAA (KD-NCAA) subgroups. Serum endocan levels were quantified via enzyme-linked immunosorbent assay. Clinical parameters including inflammatory markers were systematically analyzed using SPSS and GraphPad Prism.</div></div><div><h3>Results</h3><div>Serum endocan levels were significantly elevated in KD patients compared to HCs (median [25th–75th percentile], 1803.69 pg/ml [1478.97–2038.87] vs. 931.73 [815.57–1138.72] pg/ml, <em>P</em> < 0.001), with higher concentrations in KD-CAA versus KD-NCAA (mean ± SD, 1962.43 ± 321.48 vs. 1702.46 ± 458.54 pg/ml, <em>P</em> = 0.024).</div><div>Endocan demonstrated excellent performance in distinguishing KD patients from HCs (AUC = 0.915, 95 % CI: 0.863–0.968; sensitivity 88.6 %, specificity 85.4 %). It also showed a modest but statistically significant predictive value for CAAs within the KD cohort (AUC = 0.675, 95 % CI: 0.548–0.801; sensitivity 73.7 %, specificity 58.3 %).</div></div><div><h3>Conclusion</h3><div>Serum endocan is a high-performance biomarker for differentiating KD from HCs. Despite modest performance in predicting CAAs and undetermined specificity, it may serve as a valuable supportive tool for risk stratification in KD patients.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"196 ","pages":"Article 157052"},"PeriodicalIF":3.6000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466625001991","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Kawasaki disease (KD), an acute vasculitis of unclear etiology, is an important contributor to childhood-acquired heart disease due to coronary arterial aneurysms (CAAs). Current diagnosis lacks specific biomarkers, risking delayed treatment. Endocan, a proteoglycan implicated in vascular inflammation, may address this gap. This study evaluates serum endocan in acute KD for its utility in early KD diagnosis and CAA risk prediction.

Method

This prospective cohort study enrolled 79 KD patients and 48 healthy controls. The KD group was further divided into KD with CAA (KD-CAA) and KD non-CAA (KD-NCAA) subgroups. Serum endocan levels were quantified via enzyme-linked immunosorbent assay. Clinical parameters including inflammatory markers were systematically analyzed using SPSS and GraphPad Prism.

Results

Serum endocan levels were significantly elevated in KD patients compared to HCs (median [25th–75th percentile], 1803.69 pg/ml [1478.97–2038.87] vs. 931.73 [815.57–1138.72] pg/ml, P < 0.001), with higher concentrations in KD-CAA versus KD-NCAA (mean ± SD, 1962.43 ± 321.48 vs. 1702.46 ± 458.54 pg/ml, P = 0.024).

Endocan demonstrated excellent performance in distinguishing KD patients from HCs (AUC = 0.915, 95 % CI: 0.863–0.968; sensitivity 88.6 %, specificity 85.4 %). It also showed a modest but statistically significant predictive value for CAAs within the KD cohort (AUC = 0.675, 95 % CI: 0.548–0.801; sensitivity 73.7 %, specificity 58.3 %).

Conclusion

Serum endocan is a high-performance biomarker for differentiating KD from HCs. Despite modest performance in predicting CAAs and undetermined specificity, it may serve as a valuable supportive tool for risk stratification in KD patients.

Abstract Image

查看原文本刊更多论文

血清内能作为川崎病的双重功能生物标志物：冠状动脉瘤的早期诊断潜力和预测。

背景：川崎病（Kawasaki disease， KD）是一种病因不明的急性血管炎，是冠状动脉动脉瘤（CAAs）引起的儿童期获得性心脏病的重要因素。目前的诊断缺乏特定的生物标志物，有延迟治疗的风险。内啡肽是一种与血管炎症有关的蛋白多糖，可以弥补这一缺陷。本研究评估急性KD患者血清内啡肽在早期KD诊断和CAA风险预测中的应用。方法：本前瞻性队列研究纳入79例KD患者和48例健康对照。KD组进一步分为KD伴CAA亚组（KD-CAA）和KD非CAA亚组（KD- ncaa）。采用酶联免疫吸附法测定血清内啡肽水平。使用SPSS和GraphPad Prism对炎症指标等临床参数进行系统分析。结果：与hcc相比，KD患者血清内can水平显著升高（中位数[25 -75个百分点]，1803.69 pg/ml [1478.97-2038.87] vs. 931.73 [815.57-1138.72] pg/ml， P）。结论：血清内can是鉴别KD和hcc的高效生物标志物。尽管在预测CAAs和特异性方面表现不佳，但它可以作为KD患者风险分层的有价值的支持工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.